Literature DB >> 33341857

Is Pakistan at the cusp of an ART resistance?

Arshad Altaf1.   

Abstract

Only 10% of HIV positive individuals in Pakistan are receiving anti-retroviral therapy (ART) and the dropout rate from HIV treatment is extremely high. This short report attempts to highlight the risk of ART resistance. Pakistan National AIDS Control Programme's website reports 15,390 HIV positive persons receiving ART out of which 4,697 (30.5%) are people who inject drugs (PWIDs) among whom HIV prevalence is reported to be 38.4%. In the two large provinces of the country (Punjab and Sindh) with more than 90% burden of HIV, ART was initiated in 2,807 patients between April and September 2018, out of these 37% were lost to follow up. Many patients have cited issues related to quality of service at the ART centres as one of the reasons to not revisiting the treatment centres. HIV planners in Pakistan urgently need to make a new strategy and improve not only the quality of services but also increase the number of HIV positive persons receiving ART.

Entities:  

Keywords:  HIV, ART resistance, Pakistanzzm321990

Mesh:

Substances:

Year:  2020        PMID: 33341857     DOI: 10.5455/JPMA.30590

Source DB:  PubMed          Journal:  J Pak Med Assoc        ISSN: 0030-9982            Impact factor:   0.781


  3 in total

1.  Acceptability and feasibility of HIV self-testing among transgender people in Larkana, Pakistan: Results from a pilot project.

Authors:  Arshad Altaf; Muhammad Safdar Kamal Pasha; Ayesha Majeed; Wajid Ali; Ahmed Sabry Alaama; Muhammad Shahid Jamil
Journal:  PLoS One       Date:  2022-07-08       Impact factor: 3.752

2.  The rise in HIV cases in Pakistan: Prospective implications and approaches.

Authors:  Wajeeha Bilal Marfani; Hira Anas Khan; Mahnoor Sadiq; Oumaima Outani
Journal:  Ann Med Surg (Lond)       Date:  2022-08-24

3.  Frequency of resistance to first-line antiretroviral therapy observed among HIV patients.

Authors:  Feroz Khan; Muhammad Bilal; Muhammad Yaseen Khan; Mian Fareezuddin
Journal:  Pak J Med Sci       Date:  2022 Sep-Oct       Impact factor: 2.340

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.